title: Low frequency of ertapenem-resistant intra-abdominal isolates of Escherichia coli from Latin America: susceptibility, ESBL-occurrence, and molecular characterisation (SMART 2008-2009).
abstract: The Study for Monitoring Antimicrobial Resistance Trends is an ongoing multi-year surveillance study that tracks worldwide antimicrobial resistance trends among aerobic and facultatively anaerobic Gram-negative bacilli isolated from intra-abdominal infections. During 2008-2009, 1366 isolates of Escherichia coli were collected from 19 investigator sites in 11 Latin American countries. Of the 1366 isolates, 323 (23.6%) were extended spectrum beta-lactamase (ESBL)-positive. Overall, the most effective agents tested were imipenem, ertapenem, and amikacin with susceptibilities of ≥96%. Against ESBL-positive isolates, only imipenem and ertapenem exhibited susceptibility ≥90%. Based on the use of the new Clinical and Laboratory Standards Institute clinical breakpoints for ertapenem (resistance ≥1 μg/ml), resistance to ertapenem among all E. coli isolates was only 0.3% (4/1366) throughout the region, ranging from 0% in several countries up to 1.2% in Ecuador. Against ESBL-positive isolates only, resistance to ertapenem in Latin America overall was 0.9% (3/323), with a maximum of 9.1% (1/11) observed in Argentina.
authors.affiliation: IHMA Europe Sàrl, Epalinges, Switzerland. shawser@ihmainc.com
authors.forename: Stephen P
authors.initials: SP
authors.lastname: Hawser
authors.forename: Samuel K
authors.initials: SK
authors.lastname: Bouchillon
authors.forename: Daryl J
authors.initials: DJ
authors.lastname: Hoban
authors.forename: Robert E
authors.initials: RE
authors.lastname: Badal
authors.forename: Meredith A
authors.initials: MA
authors.lastname: Hackel
authors.forename: Christine A
authors.initials: CA
authors.lastname: Lascols
authors.forename: Maria V
authors.initials: MV
authors.lastname: Villegas
authors.forename: Flavia
authors.initials: F
authors.lastname: Rossi
mesh_terms: D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D024881:Drug Resistance, Bacterial; D000077727:Ertapenem; D004926:Escherichia coli / Q000187:drug effects* / Q000201:enzymology / Q000254:growth & development; D004927:Escherichia coli Infections / Q000453:epidemiology / Q000382:microbiology*; D006801:Humans; D059413:Intraabdominal Infections / Q000453:epidemiology / Q000382:microbiology*; D007843:Latin America / Q000453:epidemiology; D008826:Microbial Sensitivity Tests; D001618:beta-Lactamases / Q000378:metabolism*; D047090:beta-Lactams / Q000494:pharmacology*
chemical_list: D000900:Anti-Bacterial Agents; D047090:beta-Lactams; D001618:beta-Lactamases; D000077727:Ertapenem